SEC Form 4 · accession 0001209191-18-008190
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 5:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2018 | M | 4,250 | $77.31 | A | 46,202 | D | |
| Common Stock | Feb 5, 2018 | M | 4,250 | $109.14 | A | 50,452 | D | |
| Common Stock | Feb 5, 2018 | S | 8,500 | $163.08 | D | 41,952 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $77.31 | Feb 5, 2018 | M | 4,250 | D | — | Feb 4, 2024 | Common Stock | 4,250 | 0 | D |
| Stock Option (Right to Buy)F3 | $109.14 | Feb 5, 2018 | M | 4,250 | D | — | Feb 2, 2025 | Common Stock | 4,250 | 17,000 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- F2Fully vested.
- F3The option vests in 16 quarterly installments from 2/3/2015.